Want to see IBRX full AI Analyst Report?
IBRX Stock Chart & Stats
$8.19
-$0.30(-4.05%)
At close: 4:00 PM EDT
$8.19
-$0.30(-4.05%)
Day’s Range― - ―
52-Week Range$1.95 - $12.43
Previous CloseN/A
Volume8.52M
Average Volume (3M)15.00M
Market Cap
$9.29B
Enterprise Value$10.07B
Total Cash (Recent Filing)$357.37M
Total Debt (Recent Filing)$813.06M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding1,059,836,300
10 Day Avg. Volume16,890,511
30 Day Avg. Volume14,997,766
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.90
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue60.71
Enterprise Value/Gross Profit64.16
Enterprise Value/Ebitda-11.27
Forecast
1Y Price Target
$14.25Price Target Upside73.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$226.56M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And High Gross MarginTTM revenue reached $165.8M from $113.3M in 2025 while gross margin stayed near 94%, indicating rapid commercialization with substantial gross economics. If maintained, this scale can support reinvestment and improve operating leverage as ANKTIVA adoption expands, although profitability is not yet established.
Expanded U.S. Bladder Cancer IndicationThe FDA label expansion materially broadens ANKTIVA’s eligible U.S. population beyond carcinoma in situ to include papillary-only disease. This enlarges the addressable market, strengthens the product’s position in bladder cancer immunotherapy, and supports potentially broader physician adoption over the coming quarters.
International Regulatory And Indication ExpansionUAE authorization across bladder cancer and metastatic non-small cell lung cancer expands ANKTIVA’s geographic reach and clinical use cases. Approvals supported by reported durable responses and survival benefits can improve commercial access, diversify growth opportunities, and reinforce the platform’s regulatory validation.
Bears Say
Extremely Large Continuing Net LossesA TTM net loss of about $992.4M shows that current commercial revenue remains far below the cost base. Persistently negative operating and EBITDA margins could delay sustainable profitability, limit internally funded investment, and require management to prioritize cost control while expanding ANKTIVA.
Severely Negative Stockholders’ EquityNegative equity of roughly $1.05B reflects a severely weakened capital position and reduces financial flexibility despite the reduction in total debt. This structure can make future financing more consequential, constrain strategic choices, and increase the company’s exposure to dilution or other capital-raising requirements.
Persistent Cash Burn And Reliance On External CapitalThe company is still not self-funding: operating and free cash flow remain deeply negative, and TTM free cash flow deteriorated by about 52.8% year over year. Continued cash consumption may require external capital to sustain operations, limiting flexibility and increasing financing risk as commercialization develops.
ImmunityBio News
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $1.95 and its highest was $12.43 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $9.29B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Aug 04, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.14.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.07.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 1,059,836,300 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -2.797%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in IBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.25 (73.99% Upside)
$14.25 (73.99% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 95%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 575.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
252.11%
12-Months-Change
Fundamentals
Return on Equity
134.99%
Trailing 12-Months
Asset Growth
56.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ImmunityBio
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
IBRX Stock 12 Month Forecast
Average Price Target
$14.25
▲(73.99% Upside)
Technical Analysis
Ownership Overview
62.15% Insiders
4.06% Mutual Funds
0.38% Other Institutional Investors
25.42% Public Companies and Individual Investors